Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Patent
1995-06-07
1998-03-31
Kight, John
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
424 111, 424 91, A61K 4900, G01N 3100, G01N 3348
Patent
active
057335249
ABSTRACT:
The in vivo oxidation of lipids and lipid-containing molecules has been discovered to be initiated by the concurrent reaction of such lipid materials with reducing sugars such as glucose, advanced glycosylation endproducts such as AGE-peptides, or a compound which forms advanced glycosylation endproducts, to form materials or particles known as AGE-lipids. AGE-lipids have been implicated in the aging process, the abnormal formation of lipofuscin and in various disease states such as diabetes, atherosclerosis, and stroke. Methods of treating stroke, and especially inhibiting the infarct size of stroke, using agents which inhibit the formation of AGE-lipids are disclosed. Additionally, a method of screening for neuroprotective agents which can be used to reduce the size and severity of the infarct size is disclosed.
REFERENCES:
patent: 4665192 (1987-05-01), Cerami
patent: 4758583 (1988-07-01), Cerami et al.
patent: 4778752 (1988-10-01), Curtiss et al.
patent: 4900747 (1990-02-01), Vlassara et al.
patent: 4983604 (1991-01-01), Ulrich et al.
patent: 5100919 (1992-03-01), Urich et al.
patent: 5106877 (1992-04-01), Ulrich et al.
patent: 5128360 (1992-07-01), Cerami et al.
patent: 5227307 (1993-07-01), Bar-Or et al.
patent: 5238963 (1993-08-01), Cerami et al.
patent: 5246071 (1993-09-01), Williamson et al.
patent: 5246970 (1993-09-01), Williamson et al.
patent: 5264371 (1993-11-01), Miljanich et al.
patent: 5272165 (1993-12-01), Ulrich et al.
patent: 5273875 (1993-12-01), Griffith
patent: 5276053 (1994-01-01), Johnson
patent: 5334617 (1994-08-01), Ulrich et al.
patent: 5358969 (1994-10-01), Williamson et al.
patent: 5430039 (1995-07-01), Roberts-Lewis et al.
patent: 5468777 (1995-11-01), France et al.
Zimmerman et al (1995), Proc. Natl. Acad. Sci., USA, vol. 92, No. 9, pp. 3744-3748, "Neurotoxicity of Advanced Glycation End-Products During Focal Stroke and neuroprotective Effects of Aminoguenidine".
Paschen (1988), Neurochemical Pathology, vol. 9, pp. 1-20, "Polyamines in Cerebral Ischemia".
Vlassara et al., "Function of Macrophage Receptor for Vonenzymatically Glycosylated Proteins Is Modulated By Insulin Levels", Diabetes, 35(1), p. 11a (1986).
Vlassara et al., "Accumulation Of Diabetic Rat Peripheral Nerve Myelin By Macrophages Increases With The Presence Of Advanced Glycosylation Endproducts", J. Exp. Med., 160, p. 197-207 (1984).
Vlassara et al., "Recognition And Uptake Of Human Diabetic Peripheral Nerve Myelin By Macrophages", Diabetes, 34 No. 6, pp. 553-557 (1985).
Vlassara et al., "High-Affinity-Receptor-Mediated Uptake And Degrdation Of Glucose-Modified Proteins: A Potential Mechanism For The Removal Of Senescent Macromolecules", Proc. Natl. Acad. Sci. U.S.A., 82, p. 5588-5592 (1985).
Vlassara et al., "Novel Macrophage Receptor for Glucose-Modified Proteins Is Distinct from Previoiusly Described Scavenger Receptors", J. Exp. Med., 164, pp. 1301-1309 (1986).
Cerami, A. et al., "Role of Nonenzymatic Glycosylation In Atherogenesis", Journal of Cellular Biochemistry, 30, pp. 111-120 (1986).
Radoff, S. et al., "Characterization Of A Solubilized Cell Surface Bindinng Protein On Macrophages Specific For Proteins modified Nonenzymatically by Advaned Glycosylation End Products", Arch. Biochem. Biophys., 263 No. 2, pp. 418-423 (1988).
Radoff, S. et al., "Isolation of a Surface Binding Protein Specific For Advanced Glycosylation End Products From The Mouse Macrophage-Derived Cell Line Raw 264.7", Diabetes, 39, pp. 1510-1518 (1990).
Yang, Z. et al., "Two Novel Rat Liver Membrane Proeins That Bind Advanced Glycosylation Endproducts: Relationship to Macrophage Receptor For Glucose-Modified Proteins", J. Exp. Med., 174, pp. 515-524 (1991).
Witztum, J.L., and D. Steinberg, "Role of oxidized low density lipoprotein in atherogenesis", J. Clin. Invest. 88, pp. 1785-1792 (1991).
Goldstein, J.L., Y.K. Ho, S.K. Basu, and M.S. Brown, "Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol depostion", Proc. Natl. Acad. Sci. USA, 76, pp. 333-357 (1979).
Fogelman, A.H. J.S. Schecter, M. Hokom, J.S. Child, and P.A. Edwards, "Malodialdehyde alteration of low density lipoprotein leads to cholesterol accumulation in human monocyte-macrophages", Proc. Natl. Acad. Sci. USA, 77, pp. 2214-2218 (1980).
Sparrow, C.P., S. Parthesarathy, and D. Steinberg, "Amacrophage receptor that recognizes oxidized LDL but not acetylated LDL", J. Biol. Chem., 264 pp. 2599-2604 (1989).
Ross, R. "The pathogenesis of atherosclerosis", An update. New Eng. J. Med., 314, pp. 488-500 (1986).
Quinn, M.T., S. Pathasarathy, L.G. Fong, and D. Steinberg, "Oxidatively modified low density lipoprotein: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis", Proc. Natl. Sci. USA, 84, pp. 2095-2998 (1987).
Hessler, J.R., D.W. Morel, L.J. Lewis, and G.M. Chisolm, "Lipoprotein oxidation and lipoprotein-induced cytotoxicity", Arteriosclerosis, 3, pp. 215-222 (1983).
Kugiyama, K., S.A. Kerns, J.D. Morrisett, R.Roberts, and P.D. Henry, "Impairment of endothelium-dependent arterial relazation by lysolecithin in modified low-density lipoproteins", Nature, 344, pp. 160-162 (1990).
Rajavashiesth, T.B., A. Andalibi, M.C. Territo, J. A. Berliner, M. Mavab, A.M. Fogelman, and A.J. Lusis, Induction of endthelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature, 344, pp. 254-257 (1990).
Cushing, S.D., J.A. Berliner, A.J. Valente, M.Navab, F. Parhami, R. Gerrity, C.J. Schwartz, and A.M. Fogelman, "Minimally modified low denisty lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells", Proc. Natl. Acad. Sci. USA, 87, pp. 5134-5138 (1990).
Kita, T., Y. Nagano, M. Yokode, K. Ishii, N.Kume, A Ooshima, N. Yoshida, and C.Kawal, "Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal mode for familial; hypercholesterolemia", Proc. Natl. Acad. Sci. USA, 84, pp. 5928-5931 (1987).
Esterbauer, H.G. Jurgens, O. Quehenberger, and Koller, E. "Autoxidation of human low desnity lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes", J. Lipid Res., 28, pp. 505-509 (1987).
Quehenberger, O., E. Koller, G. Jurgens, and H. Esterbauer, "Investigation of lipid peroxidation in human low density lipoprotein", Free Radical Res. Commun. 3, pp. 233-242 (1987).
Steinbrecher, U.P. "Oxidation of human low density lipoprotein results in derivitization of lysine residues of apolipoprotein B by lipid peroxide decomposition products", J. Biol. Chem., 262, pp. 3603-3608 (1987).
Steinbrecher, U.P., S. Parthasarethy, D.S. Leake, J.L. Witztum, and D. Steinberg, "Modification of low desnity lipoprotein by endothelial cells involves lipid peroxodation and degradation of low density lipoprotein phospholipids", Proc. Natl. Acad. Sci. USA, 81, pp. 3883-3887 (1984).
Parthasarathy, S., E. Wieland, and D. Steinberg, "A role for endothelial cell lipoxygenase in the oxidative modifications of low density lipoprotein", Proc. Nat. Acad. Sci. USA, 86, pp. 1046-1050 (1989).
Klaassen, C.D. Heavy metals and heavy metal antagonists, In Goodman and Gilman's The Pharmacological Basis of Therapeutics, A.G. Gilman, L.S. Goodman. T.W. Rall, and F. Murad. Macmillan, New York, pp. 1592-1614 (1985).
Frei, B., Y. Yamamoto, D.Niclas, and B.H. Ames. "Evaluation of an Isolumino chemiluminescence assay for the detection of hydroperoxides in human blood plasma", Anal. Biochem., 175, pp. 120-130 (1988).
Frei, B., R. Stocker, and B.W. Ames, "Antioxidant defenses and lipid peroxidation in human blood plasma", Proc. Natl. Acad. Sci. USA, 85, pp. 9748-9752 (1988).
Bucala, R., and A. Cerami, "Advanced glycosylation: chemistry, biology, and implications for diabetes and aging", Adv. Pharmacol. 23, pp. 1-34 (1992).
Njoroge, F.G., and V.H. Monnier, "The chemistry of the Maillard reaction under physiological conditions: A review", Prog. Clin. Biol. Res., 304, pp. 85-107 (1989).
Brownlee, M., A. Cerami, and H. Vlassara,
Bucala Richard J.
Cerami Anthony
Tracey Kevin J.
Vlassara Helen
Jones Dameron
Kight John
The Picower Institute for Medical Research
LandOfFree
Methods and materials for the diagnosis and treatment of conditi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and materials for the diagnosis and treatment of conditi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and materials for the diagnosis and treatment of conditi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-48946